CompletedNCT03418831
Raloxifene Added to Usual Care for Postmenopausal Women With Schizophrenia
About this title
Read the official source —Medication studyAges 45+China
Understand this study
Who was this study for?
Listed age limits: from 45 years.
- Listed locations
- ShanghaiSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: July 17, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 45
- Sponsor
- Shanghai Mental Health Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- China
- Age range
- Over 45 Years
- Official registry ID
- NCT03418831
- Official title
Show the full official title
Selective Estrogen Receptor Modulators - Adjunctive Treatment for Negative and Cognitive Symptoms of Schizophrenia in Postmenopausal Women
Get this study by email
Recruitment & locations
CompletedShanghai
Questions about this study
Who is behind this study?
The study sponsor is Shanghai Mental Health Center, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Raloxifene Hydrochloride.
Who was this study for?
Listed age limits: from 45 years.
